Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1056, pseudogene (RNU6-1056P) is a **non-coding RNA pseudogene** annotated in the human genome[1][3]. Pseudogenes are genetic elements that have sequence similarity to known genes but have lost their protein-coding capability due to mutations, truncation, or other disruptive events[2][5]. While some pseudogenes can be transcribed and may have secondary regulatory functions—such as acting as decoys for microRNAs, generating non-coding RNAs influencing gene expression, or participating in competing endogenous RNA (ceRNA) networks—there is no evidence that RNU6-1056P plays a significant or well-characterized biological role[2][5]. It is not considered a therapeutic target, and its annotation primarily serves as a reference for genomic studies rather than biomedical or pharmacological interventions. In summary, **RNU6-1056P** is a pseudogene derived from U6 small nuclear RNA sequences; it is not a receptor, transporter, enzyme, or a targetable protein for drug action, and there is no data supporting its involvement in disease or its utility as a biomarker[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1056, pseudogene (RNU6-1056P).